drugset / Trial / NCT00343512
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Phase 2
Terminated
34 enrolled
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy. PURPOSE: To evaluate whether dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy. To determine the changes in molecular markers that occurs with single agent docetaxel, tissue will be obtained at the end of the four cycles of docetaxel (either by repeat biopsy or definitive surgery).
Timeline
- Start
- 2004-02
- Primary completion
- 2008-03
- Completion
- 2011-03
Outcome
Outcome not reported
Stopped: “closed due to competing neoadjuvant studies for a small patient population”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |